News | May 21, 2014

Wearable Holter Identifies Atrial Fibrillation and Other Cardiac Arrhythmias

Wearable Holter Zio Patch  Atrial Fibrillation iRhythm Technologies

May 21, 2014 — iRhythm Technologies Inc. announced that data from four studies presented at Heart Rhythm 2014, the Heart Rhythm Society's 35th Annual Scientific Sessions, support the use of the company's Zio Service to identify atrial fibrillation (AF) and other cardiac arrhythmias.

AF is the most common type of arrhythmia, affecting nearly 2.7 million people in the United States. Data show that AF elevates a patient's risk of ischemic stroke by five times, making its timely diagnosis critical so that proper treatment may be initiated. The Zio Service enables long-term continuous monitoring — using a novel, small, wearable patch — to detect AF and other episodic heart rhythm disturbances that are often challenging to identify using current methods.

"We presented two studies evaluating the Zio Patch in real world situations," said Mintu Turakhia, M.D., MAS, assistant professor at Stanford University. "In the first study, we found that conversion to the Zio Patch, worn on average for 11 days, compared to traditional monitors, worn on average for one day, was associated with increased yield of atrial fibrillation, which can cause stroke if untreated. In the second study, we found that in one out of every nine subjects who had heart disease but no history of arrhythmias, the Zio Patch detected arrhythmias that may lead to stroke, even though the subjects had no awareness of them. These findings underscore the importance of extended monitoring and the potential value of screening for silent heart rhythm disorders."

The following abstracts were presented at Heart Rhythm 2014:

  • "Comparative Effectiveness of 14-Day Zio Patch-Based Versus 24-Hour Holter Ambulatory ECG Monitoring for Atrial Fibrillation: Insights from an Interrupted Time Series Analysis" (Poster Session II/Poster #173) This study of 76 patients found that the Zio Service identified nearly five times as many cases of AF in the same amount of study time, compared to the Holter monitor (24% diagnostic yield vs. 5%), after the integrated healthcare system providing care phased out 24-hour Holter monitoring and replaced it with continuous monitoring for up to 14 days using the Zio Service.
  •  
  • Feasibility of Outpatient Ambulatory ECG Monitoring to Screen for Silent Atrial Fibrillation (Poster Session III/Poster #173) This study demonstrated the potential for extended screening using the Zio Service to identify AF among asymptomatic, high-risk patients in an integrated healthcare system. The Zio Service identified AF in more than 5 percent of patients with two or more risk factors, but no history of AF. The authors conclude that such detection could lead to treatments, such as stroke prevention, that could meaningfully improve survival.
  •  
  • Impact of a Novel Ambulatory ECG Monitoring Technology in an Urban Safety Net Hospital (Poster Session III/Poster #43) These interim study results demonstrated that use of the Zio Service in an urban hospital caring for underserved patients could significantly reduce wait times for ECG monitoring and results. Much of the decreases may be attributed, conclude the authors, to offloading of time-consuming operational duties such as data upload and preliminary review, which are handled by iRhythm.

Another abstract presented at the meeting was:

  • Diagnostic Yield of Ambulatory ECG Patch Monitoring in Children from a National Registry (Poster Session II/Poster #198) Researchers found that the Zio Service was able to detect cardiac arrhythmias in pediatric patients and that more than half of the arrhythmias were first detected after 48 hours of monitoring — meaning they would have been missed by the traditional 24- to 48-hour Holter monitor.

 

For more: www.irhythmtech.com


Related Content

News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — People with a small aortic annulus, a part of the heart’s anatomy where the left ventricle meets the ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 8, 2024 — People with diabetes who had suffered a heart attack derived no clinical benefit from edetate disodium ...

Home April 08, 2024
Home
Subscribe Now